Reata Pharma up 11% on potential acquisition interest

Reata Pharmaceuticals (RETA +10.9%) is up out the gate on reports that Amgen (AMGN -3.9%) is mulling acquiring assets in the space.

Reata’s lead candidate is bardoxolone methyl, in late-stage development for a kidney disorder called Alport syndrome, connective tissue disease-pulmonary arterial hypertension and focal segmental glomerulosclerosis.

Another late-stage candidate is omaveloxolone for a degenerative neuromuscular disorder called Friedreich’s ataxia.

https://seekingalpha.com/news/3536894-reata-pharma-up-11-on-potential-acquisition-interest